These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 9702769)

  • 21. Health-benefit claims for probiotic products.
    Heimbach JT
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S122-4; discussion S144-51. PubMed ID: 18181716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biotech's next big blowup?
    Stires D
    Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
    [No Abstract]   [Full Text] [Related]  

  • 23. Promoting functional foods and nutraceuticals on the Internet.
    Taylor SE; Feld HJ
    Food Drug Law J; 1999; 54(3):423-51. PubMed ID: 11797707
    [No Abstract]   [Full Text] [Related]  

  • 24. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 25. Business considerations in the development of probiotics.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S141-3; discussion S144-51. PubMed ID: 18181721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 27. Nutraceuticals tread business tightrope in Europe.
    Hodgson J
    Nat Biotechnol; 2002 Apr; 20(4):322-3. PubMed ID: 11923821
    [No Abstract]   [Full Text] [Related]  

  • 28. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 29. Market watch: Upcoming market catalysts in Q2 2013.
    Nguyen K
    Nat Rev Drug Discov; 2013 Apr; 12(4):254. PubMed ID: 23535926
    [No Abstract]   [Full Text] [Related]  

  • 30. Current marketplace for probiotics: a Japanese perspective.
    Amagase H
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S73-5; discussion S144-51. PubMed ID: 18181727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 32. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 33. Millennium mergers bring pipeline.
    Dove A
    Nat Biotechnol; 1999 Dec; 17(12):1151. PubMed ID: 10585700
    [No Abstract]   [Full Text] [Related]  

  • 34. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 35. Can you trust supplements?
    Harv Womens Health Watch; 1998 Nov; 6(3):4-5. PubMed ID: 9814132
    [No Abstract]   [Full Text] [Related]  

  • 36. Herbal Rx: the promises and pitfalls.
    Consum Rep; 1999 Mar; 64(3):44-8. PubMed ID: 10557627
    [No Abstract]   [Full Text] [Related]  

  • 37. Is the drought over for pharming?
    Kaiser J
    Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
    [No Abstract]   [Full Text] [Related]  

  • 38. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
    Falit BP
    Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
    [No Abstract]   [Full Text] [Related]  

  • 39. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative medicine: readers have their say.
    Newman WJ
    N C Med J; 1998; 59(2):69. PubMed ID: 9558886
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.